The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review

References

• Dowell D, Haegerich TM, Chou R. CDc guideline for prescribing opioids for chronic pain—united states, 2016. JAMA. 2016;315:1624–1645.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. New CDC Opioid Prescribing Guidelines: improving the Way Opioids are Prescribed for Safer Chronic Pain Treatment. [cited 2016 May 27]. Available from: http://www.wha.org/pdf/CDCguidelines_factsheet_opioids.pdf.
   Google Scholar
• US Food and Drug Administration. Fact sheet—FDA opioids action plan. [cited 2016 Apr 11]. Available from: http://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714.htm
   Google Scholar
• McCarberg BH, Nicholson BD, Todd KH, et al. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther. 2008;15:312–320.
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Patel AA, Benson CJ, et al. Physician management of moderate-to-severe acute pain: results from the Physicians Partnering Against Pain (P(3)) study. J Opioid Manag. 2013;9:401–406.
   PubMedGoogle Scholar
• Moskovitz BL, Benson CJ, Patel AA, et al. Analgesic treatment for moderate-to-severe acute pain in the United States: patients’ perspectives in the Physicians Partnering Against Pain (P3) survey. J Opioid Manag. 2011;7:277–286.
   PubMedGoogle Scholar
• Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Medicine (Malden, Mass). 2010;11:1859–1871. Epub 2010/11/03.
   PubMed Web of Science ®Google Scholar
• Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet (London, England). 2006;367:1618–1625. Epub 2006/05/16.
   PubMed Web of Science ®Google Scholar
• Shipton EA. The transition from acute to chronic post surgical pain. Anaesth Intensive Care. 2011;39:824–836. Epub 2011/10/06.
   PubMed Web of Science ®Google Scholar
• Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth. 2010;105(Suppl 1):i69–i85. Epub 2010/12/22.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Raffa RB, Taylor R Jr. Treating acute pain in light of the chronification of pain. Pain Management Nursing: Official Journal American Society Pain Management Nurses. 2014;15:380–390. Epub 2014/03/08.
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2007;15:957–965.
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380.
   PubMed Web of Science ®Google Scholar
• Papaleontiou M, Henderson CR Jr., Turner BJ, et al. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2010;58:1353–1369.
   PubMed Web of Science ®Google Scholar
• Duensing L, Eksterowicz N, Macario A, et al. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. Curr Med Res Opin. 2010;26:1579–1585.
   PubMed Web of Science ®Google Scholar
• Gregorian RS Jr, Gasik A, Kwong WJ, et al. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. Journal Pain: Official Journal American Pain Society. 2010;11:1095–1108.
   PubMed Web of Science ®Google Scholar
• Varrassi G, Muller-Schwefe GH. The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment? Curr Med Res Opin. 2012;28:823–831.
   PubMed Web of Science ®Google Scholar
• Aparasu R, McCoy RA, Weber C, et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage. 1999;18:280–288.
   PubMed Web of Science ®Google Scholar
• Lapane KL, Quilliam BJ, Benson C, et al. Gastrointestinal events after opioid treatment in nonmalignant pain: correlates of occurrence and impact on health-related quality of life. J Opioid Manag. 2013;9:205–216.
   PubMedGoogle Scholar
• Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010;44:630–640.
   PubMed Web of Science ®Google Scholar
• Suh DC, Kim MS, Chow W, et al. Use of medications and resources for treatment of nausea, vomiting, or constipation in hospitalized patients treated with analgesics. Clin J Pain. 2011;27:508–517.
   PubMed Web of Science ®Google Scholar
• Eberhart L, Koch T, Kranke P, et al. Activity-based cost analysis of opioid-related nausea and vomiting among inpatients. J Opioid Manag. 2014;10:415–422.
   PubMedGoogle Scholar
• Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27:1224–1232.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299.
   PubMed Web of Science ®Google Scholar
• Anastassopoulos KP, Chow W, Ackerman SJ, et al. Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag. 2011;7:203–215.
   PubMedGoogle Scholar
• Anastassopoulos KP, Chow W, Tapia CI, et al. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manage Care Pharm: JMCP. 2012;18:615–626.
   PubMed Web of Science ®Google Scholar
• Anastassopoulos KP, Chow W, Tapia CI, et al. Reported side effects, bother, satisfaction, and adherence in patients taking hydrocodone for non-cancer pain. J Opioid Manag. 2013;9:97–109.
   PubMedGoogle Scholar
• Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine (Phila Pa 1976). 2005;30:1331–1334.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158.
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document (Purdue Pharma L.P.): Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee. 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM461407.pdf (accessed June 15, 2017)
   Google Scholar
• FDA Briefing Document (Collegium Pharmaceutical, Inc). Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee. 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM461639.pdf (accessed June 15, 2017)
   Google Scholar
• Moore RA, Derry S, Wiffen PJ, et al. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Br J Clin Pharmacol. 2015;80:381–388.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: bioavailability and Bioequivalence Studies. 2002. Available from: https://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf (accessed July 9, 2017)
   Google Scholar
• Guidance for Industry: bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations. 2014. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf (accessed July 9, 2017)
   Google Scholar
• Devarakonda K, Kostenbader K, Giuliani MJ, et al. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials. BMC Pharmacol Toxicol. 2015;16:31. Epub 2015/11/29.
   PubMed Web of Science ®Google Scholar
• Farr SJ, Robinson CY, Rubino CM. Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. Clin Pharmacol. 2015;7:1–9. Epub 2015/02/06.
   PubMedGoogle Scholar
• Benedek IH, Jobes J, Xiang Q, et al. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther. 2011;5:455–463. Epub 2011/12/14.
   PubMed Web of Science ®Google Scholar
• Sathyan G, Xu E, Thipphawong J, et al. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol. 2007;7:2. Epub 2007/02/03.
   PubMedGoogle Scholar
• Devarakonda K, Morton T, Margulis R, et al. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions. Drug Des Devel Ther. 2014;8:1125–1134. Epub 2014/08/30.
   PubMed Web of Science ®Google Scholar
• Im YJ, Jeon JY, Kim EY, et al. An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects. Clin Ther. 2015;37:376–389. Epub 2015/01/27.
   PubMed Web of Science ®Google Scholar
• Kapil R, Nolting A, Roy P, et al. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Clin Ther. 2004;26:2015–2025. Epub 2005/04/13.
   PubMed Web of Science ®Google Scholar
• Zannikos PN, Smit JW, Stahlberg HJ, et al. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects. J Opioid Manag. 2013;9:291–300. Epub 2013/12/20.
   PubMedGoogle Scholar
• Khandave SS, Sawant SV, Joshi SS, et al. Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets. Drug Des Devel Ther. 2010;4:367–374. Epub 2010/12/15.
   PubMed Web of Science ®Google Scholar
• Bass A, Stark JG, Pixton GC, et al. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. Clin Ther. 2012;34:1601–1612. Epub 2012/06/22.
   PubMed Web of Science ®Google Scholar
• Gosai P, Ducharme MP, Godfrey AR, et al. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin(R) in Canada and US. Int J Clin Pharmacol Ther. 2013;51:895–907. Epub 2013/05/16.
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx(R) (Xtampza(R) ER). J Clin Pharmacol. 2016;57(4):500–512. Epub 2016/09/28.
   PubMed Web of Science ®Google Scholar
• Moore KT, St-Fleur D, Marricco NC, et al. A randomized study of the effects of food on the pharmacokinetics of once-daily extended-release hydromorphone in healthy volunteers. J Clin Pharmacol. 2011;51:1571–1579. Epub 2010/11/26.
   PubMed Web of Science ®Google Scholar
• Johnson F, Ciric S, Boudriau S, et al. Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther. 2010;27:846–858. Epub 2010/10/16.
   PubMed Web of Science ®Google Scholar
• Gandelman K, Lamson M, Salageanu J, et al. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. Clin Pharmacol Drug Dev. 2015;4:370–376.
   PubMed Web of Science ®Google Scholar
• Franke RM, Morton T, Devarakonda K. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Drug Des Devel Ther. 2015;9:4587–4597. Epub 2015/09/01.
   PubMed Web of Science ®Google Scholar
• Harris JD. Management of expected and unexpected opioid-related side effects. Clin J Pain. 2008;24(Suppl 10):S8–S13.
   PubMed Web of Science ®Google Scholar
• McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain: Off J Am Pain Soc. 2003;4:231–256.
   PubMed Web of Science ®Google Scholar
• Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347–1354.
   PubMed Web of Science ®Google Scholar
• HYSINGLA ER [prescribing information]. Stamford (CT): Purdue Pharma LP; 2014.
   Google Scholar
• EMBEDA [prescribing information]. Bristol (TN): King Pharmaceuticals, Inc; 2009.
   Google Scholar
• TARGINIQ ER [prescribing information]. Stamford (CT): Purdue Pharma LP; 2014.
   Google Scholar
• MORPHABOND [prescribing information]. Valley Cottage (NY): Inspirion Delivery Technologies LLC; 2015.
   Google Scholar
• ZOHYDRO ER [prescribing information]. Morristown (NJ): Pernix Therapeutics, LLC; 2016.
   Google Scholar
• ARYMO ER [prescribing information]. Wayne (PA): Egalet US Inc.; 2017.
   Google Scholar
• VANTRELLA ER [prescribing information]. North Wales (PA): Teva Pharmaceuticals USA, Inc; 2017.
   Google Scholar
• Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol. 2011;2011:187103. Epub 2011/03/16.
   PubMedGoogle Scholar
• Jannetto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genome Med. 2010;2:66. Epub 2010/09/22.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV. Quantifying the impact of drug-drug interactions associated with opioids. Am J Manag Care. 2011;17(Suppl 11):S288–S292. Epub 2011/10/26.
   PubMedGoogle Scholar